Sign in Subscribe
Pharmaceutical industry

Antisoma Reaches Patient Recruitment Target in AS1404 Lung Cancer Trial

Strategic Insights

— 1 min read

Antisoma, a biopharmaceutical company developing novel products for cancer treatment, has announced that it has reached the patient recruitment target for its phase II trial of AS1404 in non-small cell lung cancer. This milestone keeps the company on track to report the first efficacy data from the trial during the year. The trial, which is part of a broader program evaluating the benefit of adding AS1404 to standard chemotherapy treatments in lung, prostate, and ovarian cancers, has recruited around seventy patients across Europe, Australia, and New Zealand. The trial's results are expected to provide proof of concept for AS1404, a drug with significant market potential.

Key Takeaways:

  • Antisoma has reached the patient recruitment target for its phase II trial of AS1404 in non-small cell lung cancer, recruiting around seventy patients across Europe, Australia, and New Zealand.
  • The trial is a randomized controlled study comparing the efficacy of standard chemotherapy treatment with and without the addition of AS1404.
  • AS1404 (DMXAA) is a small-molecule vascular disrupting agent that targets the blood vessels that nourish tumors.
  • Preclinical evidence shows that AS1404 enhances the efficacy of chemotherapy drugs and complements their action on tumors.
  • Antisoma's CEO Glyn Edwards credited the company's clinical group and investigators for their efforts in rapidly recruiting patients into the trial.
  • The company expects to report the first efficacy data from the trial during the year, with a steady stream of efficacy data emerging from its ovarian and prostate cancer trials soon.

Statistics:

  • 70 patients have been recruited for the AS1404 lung cancer trial across Europe, Australia, and New Zealand.
  • The trial is a randomized controlled study comparing the efficacy of standard chemotherapy treatment with and without the addition of AS1404.
  • The company has a broad program conducting three separate phase II trials in lung, prostate, and ovarian cancers evaluating the benefit of adding AS1404 to standard chemotherapy treatments.

Sources:

  • Antisoma plc (C) 2005 PRIMEZONE, All rights reserved.
  • The Auckland Cancer Society Research Centre, University of Auckland, New Zealand, where AS1404 was discovered by Professors Bruce Baguley and William Denny and their teams.

Read more